Advertisement

Suppliers' News

Kemin becomes majority shareholder in animal vaccine company

The company is focusing on strengthening its place in the global vaccine manufacturing and distribution market with its increased partnership in MEVAC and investment in its sister company.

Kemin
April 5, 2021

Kemin Industries is growing its presence in the global vaccine market by becoming the majority shareholder of MEVAC, an animal vaccine manufacturer based in Cairo, Egypt, and a shareholder in MEVAC's sister company, UVAC, to further expand Kemin's portfolio in the global animal vaccine market.

“We entered into a partnership with MEVAC over a decade ago and are thrilled to become the majority shareholder,” said Chris Nelson, president and CEO, Kemin Industries. “Kemin and MEVAC share the goal of transforming lives and creating a sustainable future – one in which non-antibiotic alternatives are becoming more and more important to customers. By extending our partnership to MEVAC's sister company, UVAC, we can do even more to bring our innovations to animal vaccines.”

First investing in the MEVAC in 2010, Kemin has increased its participation in the Egyptian-based company over the years. In 2019, Kemin increased its share in MEVAC and received the right to distribute its vaccines globally, outside the Arabic-speaking countries in the Middle East already served by MEVAC.

“As Kemin has grown its partnership with MEVAC, our capabilities and technologies have expanded, as well, and we are thrilled to bring this beneficial cooperation to UVAC,” said Magdy El Sayed, founder, MEVAC and UVAC. “We share a commitment to advancing technology and accessibility of animal vaccines, and together, we can create an even greater impact.”

As part of its investment in MEVAC, Kemin has access to a modern vaccine plant with production and R&D capabilities to support future growth.